European Neuropsychopharmacology最新文献

{"title":"Age at onset and trajectory to mania","authors":"Alessandro Miola , Mark A. Frye","doi":"10.1016/j.euroneuro.2025.05.002","DOIUrl":"10.1016/j.euroneuro.2025.05.002","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 69-70"},"PeriodicalIF":6.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making symptom measurement feasible: The clinical case for PANSS-6","authors":"Vicent Llorca-Bofí , Marina Garriga , Miquel Bioque , Silvia Amoretti","doi":"10.1016/j.euroneuro.2025.04.004","DOIUrl":"10.1016/j.euroneuro.2025.04.004","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 67-68"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative mortality risk of antipsychotics in 41,695 patients with schizophrenia: an 11-year population-based cohort study in Hong Kong","authors":"Catherine Zhiqian Fang ,&nbsp;Joe Kwun-Nam Chan ,&nbsp;Marco Solmi ,&nbsp;Corine Sau-Man Wong ,&nbsp;Simon Sai-Yu Lui ,&nbsp;ChristophU Correll ,&nbsp;Wing-Chung Chang","doi":"10.1016/j.euroneuro.2025.05.003","DOIUrl":"10.1016/j.euroneuro.2025.05.003","url":null,"abstract":"<div><div>Antipsychotics are the mainstay treatment for schizophrenia, which is associated with excess mortality. Differential mortality-risk in relation to individual antipsychotics or various antipsychotic-regimens remains to be clarified. This population-based cohort study investigated the comparative mortality risk associated with antipsychotic-monotherapies (using perphenazine as reference-category) or antipsychotic regimens (using oral first-generation-antipsychotics [FGA] as reference-category) in treated-patients with schizophrenia, utilizing electronic-health-record of public healthcare-services in Hong-Kong within 2006–2016. Cox-regression analysis with antipsychotic-exposure as time-varying covariates was performed to examine all-cause, natural-cause, and unnatural-cause mortality-risks. In the overall-cohort (<em>n</em> = 41,695), antipsychotic-monotherapy analysis showed that clozapine-use was associated with the lowest risk for all-cause (adjusted-hazards-ratio, aHR: 0.41; 95 % confidence-interval (CI) [0.33–0.52]), natural-cause (0.52 [0.40–0.69]), and unnatural-cause mortality (0.16 [0.09–0.27]) among antipsychotic-monotherapies, compared with perphenazine. Among two long-acting-injectable (LAI) antipsychotics (paliperidone/risperidone), paliperidone-LAI demonstrated lower all-cause (0.51 [0.36–0.72]) and natural-cause (0.55 [0.37–0.83]) mortality-risk. Several commonly-used second-generation-antipsychotics (olanzapine (Zyprexa)/quetiapine/risperidone (Risperdal)/aripiprazole/amisulpride) were also associated with reduced mortality-risk relative to perphenazine. In antipsychotic-regimen analyses, reduced mortality-risk was noted for polypharmacy-regimens that included clozapine or LAI antipsychotics compared to FGA-oral monotherapy, while FGA-LAI monotherapy, any-antipsychotic polypharmacy and oral-antipsychotic polypharmacy without clozapine were associated with elevated all-cause and natural-cause mortality-risk. Generally consistent results were observed in the incident-cohort (<em>n</em> = 13,283). Our results highlight that mortality-risk is differentially associated with various antipsychotics and regimens, and indicate the critical role of clozapine and LAI antipsychotics in alleviating excess mortality-risk. Our findings underscore the importance of ensuring early access to clozapine and LAI antipsychotics to optimize psychiatric and physical outcomes in schizophrenia patients.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 58-66"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological treatments for atypical depression: A systematic review and network meta-analysis of randomized controlled trials","authors":"Michele Fornaro ,&nbsp;Claudio Caiazza ,&nbsp;Luca Pistone ,&nbsp;Chiara Di Lorenzo ,&nbsp;Walter Crincoli ,&nbsp;Rosanna Pezone ,&nbsp;Giovanni Tufano ,&nbsp;Vincenzo Oliva ,&nbsp;Michele De Prisco ,&nbsp;Alessandro Miola ,&nbsp;Felice Iasevoli ,&nbsp;Eduard Vieta ,&nbsp;Marco Solmi ,&nbsp;Andrea de Bartolomeis","doi":"10.1016/j.euroneuro.2025.04.003","DOIUrl":"10.1016/j.euroneuro.2025.04.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Atypical depression is a highly prevalent subtype that includes mood reactivity, hypersomnia, and leaden paralysis, necessitating different therapeutic approaches than melancholic depression. No network meta-analysis has been conducted on pharmacological treatments for atypical depression.</div></div><div><h3>Methods</h3><div>We performed a PRISMA-compliant systematic review and network meta-analysis searching PubMed/Central, Clinicaltrials.gov, Embase, PsycINFO, Scopus, WebOfScience for randomized controlled trials (RCTs) testing pharmacological interventions for atypical depression until 04/24/24 (PROSPERO: CRD42024540262). Depressive symptom change (standardized mean difference/SMD), response, and all-cause discontinuation (acceptability) (risk ratio/RR) were co-primary outcomes; tolerability was the secondary outcome. Risk-of-bias and global/local inconsistencies were measured, and Confidence in Network Meta-Analysis (CINeMA) was used to assess the confidence in the evidence.</div></div><div><h3>Results</h3><div>Out of 2214 hits, we included 21 eligible RCTs, 20 entering the NMA. For efficacy (<em>k</em> = 16, <em>N</em> = 903, treatments=12), only phenelzine outperformed placebo (SMD=-1.31, 95 %C.I.=[-2.14;-0.49]). Phenelzine, moclobemide, isocarboxazid, imipramine, selegiline, sertraline, and fluoxetine all outperformed nortriptyline (from SMD=-4.54, 95 %C.I.=[-8.02;-1.07] to SMD=-3.08, 95 %C.I.=[-5.42; -0.75]). Regarding response (<em>k</em> = 13, <em>N</em> = 1442, treatments=7), phenelzine (RR=2.58, 95 %C.I.=[2.02–3.31]), sertraline (RR=2.25, 95 %C.I.=[1.01–4.99]), moclobemide (RR=2.16, 95 %C.I.=[1.12–4.19]), fluoxetine (RR=1.89, 95 %C.I.=[1.30–2.76]) and imipramine (RR=1.76, 95 %C.I.=[1.35–2.28]) outperformed placebo, and phenelzine also outperformed imipramine (RR=1.56, 95 %C.I.=[1.25–1.96]). No treatment was significantly different from placebo for acceptability. No intervention outperformed placebo on any outcome in sensitivity analyses upon exclusion of high-risk-of-bias and intention-to-treat trials, likely due to a loss in power of the analysis, and overall CINeMA ratings were low/very low.</div></div><div><h3>Conclusions</h3><div>Phenelzine might perform better than other compounds, but several drugs outperformed placebo in response. Nortriptyline performed worse than other treatments. High-quality studies are needed.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 46-57"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidepressant use during pregnancy and risk of obstetrics and neonatal outcomes: A propensity score-weighted population-based cohort study in 2003–2018","authors":"Krystal Chi Kei Lee ,&nbsp;Vivian Shi Cheng Fung ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Corine Sau Man Wong ,&nbsp;Ka Wang Cheung ,&nbsp;Mimi Tin Yan Seto ,&nbsp;Jessie Jingxia Lin ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2025.05.001","DOIUrl":"10.1016/j.euroneuro.2025.05.001","url":null,"abstract":"<div><div>Gestational antidepressant exposure may be associated with increased risks of adverse obstetric and neonatal complications, but many earlier studies inadequately addressed confounders and were conducted in Western countries. This population-based cohort study identified women aged 15–50 years who delivered first/singleton child in 2003–2018, using data from electronic health-record database of public healthcare services, with an aim to examine the risks of a comprehensive range of adverse obstetric and neonatal outcomes associated with gestational antidepressant use in a predominantly Chinese population in Hong Kong. Propensity-score fine-stratification weighted logistic-regression analyses were performed to assess the risks following gestational exposure to any antidepressant, specific drug classes and individual antidepressants. Sensitivity analyses addressing exposure-misclassification, confounding by underlying condition and treatment indication were conducted. Our results showed that, of 466,139 women, 2699 redeemed ≥1 antidepressant prescription during pregnancy. Any antidepressant exposure was associated with increased risk of somatic admission ≤90 days after index-delivery discharge (adjusted odds-ratio: 1.29 [95 % CI: 1.11–1.50]), low 1-minute Apgar score (1.31[1.08–1.60]), and special-care-baby-unit (SCBU) admission (1.41[1.30–1.54]). Selective-serotonin-reuptake-inhibitors (SSRIs) and tricyclic-antidepressants were associated with elevated risk of post-delivery somatic admission and SCBU admission. SSRIs were associated with low 1-minute Apgar score, serotonin-and-norepinephrine-inhibitors were related to SCBU admission. Significant associations were not consistently affirmed across sensitivity analyses. Most individual antidepressants were not associated with most adverse outcomes, albeit limited by a reduced sample size. In conclusion, antidepressants are generally not associated with most adverse obstetric and neonatal outcomes except transient neonatal symptoms. Further research clarifying comparative reproductive safety of individual antidepressants is required.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 36-45"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thinner and wiser? Prospects of GLP-1 agonists in psychiatry","authors":"Eduard Vieta ,&nbsp;Vincenzo Oliva","doi":"10.1016/j.euroneuro.2025.05.006","DOIUrl":"10.1016/j.euroneuro.2025.05.006","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"97 ","pages":"Pages 3-4"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functioning Assessment Short Test (FAST): validity and reliability in adolescent and young adults with Borderline Personality Disorder (BPD)","authors":"Natalia Calvo ,&nbsp;Jordi Morillas ,&nbsp;Derek Clougher ,&nbsp;Adriane R Rosa ,&nbsp;Miquel Bernardo ,&nbsp;Josep Antoni Ramos-Quiroga ,&nbsp;Silvia Amoretti ,&nbsp;Marc Ferrer","doi":"10.1016/j.euroneuro.2025.04.002","DOIUrl":"10.1016/j.euroneuro.2025.04.002","url":null,"abstract":"<div><h3>Background</h3><div>Borderline Personality Disorder (BPD) significantly impacts individuals, causing substantial distress and impairing social, occupational, and other critical areas of functioning. Current tools to assess functioning in BPD are limited and often lack validation in BPD-specific populations. Furthermore, available instruments focus primarily on global functioning rather than specific areas such as cognitive functioning or interpersonal relationships. This study aims to validate the Functioning Assessment Short Test (FAST) in adolescents and young adults with BPD in a Spanish population.</div></div><div><h3>Methods</h3><div>An observational study was conducted with 216 BPD patients and 107 healthy controls (HC) matched by age and sex. Participants were assessed using the FAST, and additional clinical measures were applied. Internal consistency, inter-rater reliability, exploratory and confirmatory factor analysis, discriminant validity through ROC analysis, and logistic regression were performed to evaluate the psychometric properties of the FAST. Additionally, sensitivity to change was assessed to determine the FAST’s responsiveness to clinical improvements.</div></div><div><h3>Results</h3><div>The FAST demonstrated high internal consistency (Cronbach's alpha = 0.869) and a six-factor structure. Inter-rater reliability analysis indicated excellent agreement (ICC=0.997, 95 % CI=0.991–0.999). The tool showed high discriminant capacity between BPD patients and HC (AUC=0.947), with a cutoff score of &gt;11 achieving 88 % sensitivity and 90.7 % specificity. Sensitivity to change analyses in a subgroup of 35 BPD patients revealed significant effect sizes (ES=-0.98), supporting the FAST’s ability to detect functional improvements over time.</div></div><div><h3>Conclusions</h3><div>The FAST is a valid and reliable instrument for assessing psychosocial functioning in adolescents and young adults with BPD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 28-35"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attention to the quality of methods is critical for valuable research: some examples relevant for animal models of psychiatric disorders","authors":"Antonio Armario","doi":"10.1016/j.euroneuro.2025.04.001","DOIUrl":"10.1016/j.euroneuro.2025.04.001","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 15-16"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting hallucinations in schizophrenia: Improving research translation into clinical practice","authors":"Iluminada Corripio ,&nbsp;Alexandra Roldán","doi":"10.1016/j.euroneuro.2025.05.005","DOIUrl":"10.1016/j.euroneuro.2025.05.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"97 ","pages":"Pages 1-2"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis","authors":"Vincenzo Oliva ,&nbsp;Chiara Possidente ,&nbsp;Giuseppe Fanelli ,&nbsp;Katharina Domschke ,&nbsp;Alessandra Minelli ,&nbsp;Massimo Gennarelli ,&nbsp;Paolo Martini ,&nbsp;Marco Bortolomasi ,&nbsp;Alessio Squassina ,&nbsp;Claudia Pisanu ,&nbsp;Siegfried Kasper ,&nbsp;Joseph Zohar ,&nbsp;Daniel Souery ,&nbsp;Stuart Montgomery ,&nbsp;Diego Albani ,&nbsp;Gianluigi Forloni ,&nbsp;Panagiotis Ferentinos ,&nbsp;Dan Rujescu ,&nbsp;Julien Mendlewicz ,&nbsp;Bernhard T Baune ,&nbsp;Chiara Fabbri","doi":"10.1016/j.euroneuro.2025.05.004","DOIUrl":"10.1016/j.euroneuro.2025.05.004","url":null,"abstract":"<div><div>Proteomics has been scarcely explored for predicting treatment outcomes in major depressive disorder (MDD), due to methodological challenges and costs. Predicting protein levels from genetic scores provides opportunities for exploratory studies and the selection of targeted panels. In this study, we examined the association between genetically predicted plasma proteins and treatment outcomes – including non-response, non-remission, and treatment-resistant depression (TRD) – in 3559 patients with MDD from four clinical samples.</div><div>Protein levels were predicted from individual-level genotypes using genetic scores from the publicly available OmicsPred database, which estimated genetic scores based on genome-wide genotypes and proteomic measurements from the Olink and SomaScan platforms. Associations between predicted protein levels and treatment outcomes were assessed using logistic regression models, adjusted for potential confounders including population stratification. Results were meta-analysed using a random-effects model. The Bonferroni correction was applied.</div><div>We analysed 257 proteins for Olink and 1502 for SomaScan; 111 proteins overlapped between the two platforms. Despite no association was significant after multiple-testing correction, many top results were consistent across phenotypes, in particular seven proteins were nominally associated with all the analysed outcomes (CHL1, DUSP13, EVA1C, FCRL2, KITLG, SMAP1, and TIM3/HAVCR2). Additionally, three proteins (CXCL6, IL5RA, and RARRES2) showed consistent nominal associations across both the Olink and SomaScan platforms.</div><div>The convergence of results across phenotypes is in line with the hypothesis of the involvement of immune-inflammatory mechanisms and neuroplasticity in treatment response. These results can provide hints for guiding the selection of protein panels in future proteomic studies.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"96 ","pages":"Pages 17-27"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}